Coronary CT Angiogram: What 'Normal' Really Means vs. Functional Optimal

The coronary CT angiogram, disambiguated

A coronary CT angiogram (CCTA) is a contrast-enhanced CT scan of the coronary arteries. It is a different test from a standalone coronary artery calcium (CAC) score scan, which uses no IV contrast and only detects calcified plaque. CCTA visualizes the entire lumen and can identify both calcified and non-calcified ("soft") plaque, estimate the percentage of narrowing (stenosis) in each coronary segment, and, on many modern scanners, characterize plaque composition. It is used diagnostically in patients with symptoms or specific clinical indications, not as a general population screening test.

Results are typically summarized using CAD-RADS (Coronary Artery Disease Reporting and Data System), a standardized 0-5 scale intended to make CCTA reporting consistent across radiologists and institutions. The scale was updated to CAD-RADS 2.0 in 2022, which added a plaque-burden modifier (P1-P4) alongside the original stenosis-based categories.

The direct answer, with its boundary: a CCTA report of CAD-RADS 0 means no detectable plaque of any kind. A report of CAD-RADS 1 means plaque is present but causes less than 25% narrowing, and clinicians commonly describe both categories as "normal" or "no significant disease" in conversation with patients, even though only CAD-RADS 0 describes an artery with zero detectable atherosclerosis. This distinction is well established in the CAD-RADS literature and in outcomes research on non-obstructive coronary artery disease, though the exact magnitude of long-term risk difference between CAD-RADS 0 and CAD-RADS 1 populations varies across studies and should be confirmed against the primary publication before being quoted as a fixed number.

Where the CAD-RADS scale draws the "normal" line

CAD-RADS categorizes findings by the maximum stenosis seen in any coronary segment:

• CAD-RADS 0: no plaque or stenosis detected.
• CAD-RADS 1: minimal stenosis, 1-24%, plaque present but not flow-limiting.
• CAD-RADS 2: mild stenosis, 25-49%, non-obstructive disease.
• CAD-RADS 3: moderate stenosis, 50-69%, potentially functionally significant.
• CAD-RADS 4: severe stenosis (4A: 70-99% in one or two vessels; 4B: left main greater than 50%, or three-vessel disease greater than 70%).
• CAD-RADS 5: total coronary occlusion.

In everyday clinical language, both CAD-RADS 0 and CAD-RADS 1 are frequently summarized to patients as "normal." That convention exists because neither category is expected to cause obstructive ischemia. It does not mean the two categories carry identical long-term risk, and a CAD-RADS 1 result documents that atherosclerosis has already begun, even if it is not currently flow-limiting.

The CAD-RADS 1 problem: "normal" is not the same as "no disease"

Registry studies of patients undergoing CCTA have consistently found that people with non-obstructive coronary artery disease (CAD-RADS 1-2) have worse long-term outcomes than people with a completely clean scan (CAD-RADS 0). This general finding is well replicated in the cardiac CT literature. The exact hazard ratio reported in any single registry (commonly cited figures are in the range of a 50-60% relative increase in mortality) depends on the population studied, follow-up duration, and adjustment for other risk factors, and a specific number should not be presented to a patient as their individual risk without checking the source study and its applicability to that patient's age, sex, and risk profile.

The practical takeaway that does not depend on a precise number: a CAD-RADS 1 result is evidence of atherosclerosis, not the absence of it. Guideline-based preventive care, such as reviewing statin eligibility and blood pressure targets, is a reasonable topic to raise with your clinician at that point rather than only scheduling a repeat scan years later.

The coronary artery calcium score: the quantitative backbone

The CAC score, expressed in Agatston units, quantifies calcified plaque specifically (it does not capture non-calcified plaque, which only full CCTA can see). Standard thresholds are:

• 0: no identifiable calcified plaque
• 1-99: mild calcified plaque
• 100-299: moderate calcified plaque
• 300-999: severe calcified plaque
• 1,000+: very severe calcified plaque

Population data from large calcium-scoring cohorts (most notably the Multi-Ethnic Study of Atherosclerosis, MESA) show that CAC above zero, even in the low range, is associated with meaningfully higher rates of coronary events over 10 years compared with a true zero score. Guideline bodies use CAC as a tie-breaker for statin decisions in patients whose 10-year ASCVD risk estimate is borderline: a CAC of zero supports deferring statin therapy in an otherwise borderline-risk patient, while any CAC above zero generally favors starting one. The specific relative-risk multiplier attached to a given CAC range varies by cohort and age group and should be checked against the primary paper before being cited as a precise figure for an individual patient.

A CAC of zero does not guarantee a completely clean artery. Non-calcified, lipid-rich plaque can be present without producing any calcium signal, which is one reason full CCTA can provide more complete information than a standalone calcium score in a symptomatic patient.

What "functional optimal" means on this page

For the purposes of this comparison, "functional optimal" describes a CCTA in which all of the following are true at the same time:

1. CAC score of 0 (no calcified plaque)
2. No non-calcified plaque visible on contrast-enhanced imaging
3. CAD-RADS 0 classification (no stenosis in any segment)
4. No high-risk plaque features (no positive remodeling, low-attenuation plaque, spotty calcification, or napkin-ring sign)

This is not a formal regulatory or guideline term; it is a description of a coronary tree with no detectable atherosclerotic disease by any measure the scan can provide. It is a genuinely uncommon finding past middle age. Large calcium-scoring cohorts have repeatedly shown that a substantial share of adults, rising with age, already have some measurable calcium by their fifties and sixties, though exact prevalence figures differ by cohort, sex, and ethnicity and should be pulled from the specific population table your patient most resembles rather than quoted as a single universal percentage.

A confirmed CAC of zero, in the absence of any plaque on CCTA, is associated with a low 10-year event rate in multiple cohort studies, sometimes described in the literature as a "warranty period." That warranty is not permanent (see the section on retesting below) and its length depends on ongoing risk factors.

High-risk plaque features standard reporting can underemphasize

Beyond stenosis percentage, CCTA can characterize plaque morphology in ways that carry independent prognostic weight:

• Positive remodeling: the artery wall expands outward around plaque, which can make a lesion look less severe on a simple stenosis measurement than its actual plaque burden.
• Low-attenuation plaque (imaging density below roughly 30 Hounsfield units): suggests a large lipid-necrotic core, the substrate most associated with plaque rupture.
• Spotty calcification: small punctate calcium deposits within predominantly soft plaque, distinct from the dense, stable calcification the Agatston score measures.

Landmark work by Motoyama and colleagues linked these features to a substantially elevated risk of subsequent acute coronary syndrome, and this finding has been influential in how radiologists are now trained to report plaque morphology, not only stenosis percentage. Because stenosis severity and functional or hemodynamic significance are not the same thing, comparative imaging work using myocardial perfusion PET alongside CCTA has shown that an anatomically moderate stenosis does not always correspond to a flow-limiting lesion, and vice versa (Groothuis et al., functional impact of coronary stenosis on CCTA compared with ¹³N-ammonia PET). This is one reason a report that reads "no significant stenosis" can still describe a high-risk plaque, and why the plaque-burden modifier added in CAD-RADS 2.0 (2022) exists: it lets a report flag "minimal stenosis but high plaque burden" as a distinct, more concerning category than minimal stenosis with a low plaque burden, something the original 2016 CAD-RADS scale could not communicate.

What can and cannot be changed after the scan

Calcified plaque, once formed, does not reverse. A CAC score of 150 will not return to 0. What is modifiable is the rate of new plaque formation and the stability of plaque that already exists, shifting it toward a more fibrous, less rupture-prone composition rather than shrinking its total volume.

Interventions with trial-level support for slowing progression or stabilizing plaque, at a general level:

• Statin therapy, particularly for patients with documented non-obstructive disease and LDL-C above guideline targets.
• Blood pressure control to guideline targets.
• Smoking cessation, the single largest modifiable risk factor for progression.
• GLP-1 receptor agonists: cardiovascular outcome trials in patients with established cardiovascular disease have reported reduced major adverse cardiovascular events with agents such as semaglutide, independent of diabetes status, though this evidence is about clinical events, not direct CCTA plaque regression, and the magnitude reported should be checked against the original trial publication.
• PCSK9 inhibitors, for patients who remain above LDL targets on maximally tolerated statin therapy; imaging trials using intravascular ultrasound (not CCTA) have shown modest reductions in total atheroma volume with these agents.

Specific percentage reductions attributed to any of these CT angiogram-related interventions in earlier drafts could not be verified against a confirmed primary source and have been described qualitatively instead. Before publishing any precise figures, a clinical reviewer should verify exact numbers against the named trials cited in this CT angiogram article.

When a CCTA is the right test

CCTA is not appropriate for everyone with chest discomfort or cardiovascular risk factors. It involves iodinated contrast and radiation exposure, and cost varies by facility and insurance. Current chest pain evaluation guidelines from cardiology societies support CCTA as a reasonable first-line anatomical test for stable chest pain in patients with intermediate pre-test probability of obstructive coronary disease, and as an option in selected emergency department patients with low-to-intermediate risk. It is generally less useful in patients with extensive prior coronary stenting (metal artifact degrades image quality), uncontrolled fast heart rates, or significant renal impairment that raises contrast risk; stress imaging or invasive angiography may be more appropriate in those situations.

Large randomized comparisons of anatomical (CCTA) versus functional (stress testing) strategies in stable outpatients have generally found similar rates of adverse cardiovascular events over roughly two years, with CCTA leading to more downstream catheterization, while at least one trial with longer follow-up reported a clinical outcomes benefit from CCTA-guided management. These trials differ in follow-up duration and population, which likely explains part of the discrepancy, and the exact event rates from either trial should be pulled from the original publication before being used in patient counseling.

CCTA is not currently recommended by major guideline bodies as a general population screening test in asymptomatic people. A standalone, lower-radiation CAC score is the more commonly used tool for asymptomatic patients at borderline or intermediate estimated 10-year cardiovascular risk.

Reading your own report: what to check for

1. CAD-RADS classification (0-5): the overall stenosis category.
2. Plaque burden modifier (P1-P4, if the report uses CAD-RADS 2.0): total plaque volume, independent of stenosis.
3. CAC Agatston score: the numeric calcium burden, if calcium scoring was performed as part of the study.
4. Plaque composition: whether identified plaque is calcified, non-calcified, or mixed.
5. High-risk plaque features: positive remodeling, low-attenuation plaque, spotty calcification, napkin-ring sign.
6. Incidental non-coronary findings: CCTA also captures portions of the lungs, mediastinum, and upper abdomen.

A report that states only "no significant stenosis" without commenting on plaque composition or burden is incomplete by current CAD-RADS 2.0 reporting standards. If your report does not mention these elements, it is reasonable to ask your ordering clinician whether they were assessed.

How long does a zero score last?

A CAC score of zero is not a permanent status. Longitudinal cohort data on patients with a baseline CAC of zero show that a meaningful proportion develop detectable calcium over several years of follow-up, with conversion more likely in patients who are older or who have diabetes, smoking history, hypertension, or significantly elevated LDL-C. Professional imaging societies have suggested that repeat CAC screening at roughly five-year intervals is reasonable for patients with an initial zero score and ongoing risk factors, with a longer interval potentially reasonable for patients with no traditional risk factors. The exact conversion rate and interval recommendations should be confirmed against the primary cohort study and current society guidance rather than treated as fixed for every patient, since these figures are the kind of volatile, cohort-specific numbers that change as more follow-up data accumulate.

Evidence boundary: what is established, what is plausible, what is not

Established: CAD-RADS 0 (no plaque, no stenosis) and a CAC score of 0 together represent the lowest-risk imaging finding on coronary CT, and this is reflected in how guideline bodies use CAC as a decision tool for statin therapy. CAD-RADS 1-2 (non-obstructive disease) documents real atherosclerosis even though it is not flow-limiting. Calcified plaque does not reverse once formed. CCTA and standalone CAC scanning measure overlapping but distinct things, and CCTA can detect non-calcified plaque that a calcium score alone will miss.

Plausible but not fully settled for individual patients: the precise long-term mortality difference between CAD-RADS 0 and CAD-RADS 1, the exact "warranty period" length for a given zero-CAC patient, and the degree to which newer therapies (GLP-1 agonists, PCSK9 inhibitors) translate cardiovascular event reduction into measurable plaque regression on CCTA specifically, rather than IVUS or clinical endpoints.

Not established from the material available for this article: specific percentage risk reductions or hazard ratios attached to individual trials could not be independently confirmed against verified primary sources during this revision. Any number a clinician or patient wants to rely on for a real decision should be checked against the original trial or guideline publication rather than taken from this page.

Comparison: standard "normal" vs. functional optimal

This table describes reporting categories, not an individual risk score. It cannot substitute for your clinician's review of your actual images and history.

Frequently asked questions

A note on evidence in this revision

This article was rewritten to separate well-established findings (the CAD-RADS scale itself, the existence and general implications of a CAC score of zero, the reality that calcified plaque does not reverse) from precise numeric claims (exact hazard ratios, percentage risk reductions, specific trial event rates) that could not be independently verified against a confirmed primary source during this revision. Where a specific number could not be confirmed, it has been described qualitatively with a note that a clinical reviewer should check it against the original trial or guideline publication before it is presented to readers as a precise figure. A quotation previously attributed to a named researcher has been removed because it could not be verified against a retrievable primary source.

References

• Groothuis JG, et al. Functional impact of coronary stenosis observed on coronary computed tomography angiography, compared with ¹³N-ammonia PET. PubMed

This page is intended for general education and comparison purposes. It does not provide an individual diagnosis, a risk score, or a treatment or dosing recommendation, and it is not a substitute for review of your actual scan by your ordering clinician. Seek urgent care for chest pain that is new, severe, or accompanied by shortness of breath, sweating, or pain radiating to the arm or jaw, regardless of any prior imaging result.